Carolinas Wealth Consulting’s Ionis Pharmaceuticals IONS Stock Holding History

Carolinas Wealth Consulting’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-161	Closed	-$7.13K	–	1020
2023 Q3	$7.13K	Hold	161	–	–	﹤0.01%	563
2023 Q2	$6.61K	Hold	161	–	–	﹤0.01%	644
2023 Q1	$5.75K	Sell	161 -26	-14%	-$976	﹤0.01%	669
2022 Q4	$7.06K	Hold	187	–	–	﹤0.01%	657
2022 Q3	$8K	Hold	187	–	–	﹤0.01%	600
2022 Q2	$7K	Hold	187	–	–	﹤0.01%	626
2022 Q1	$7K	Hold	187	–	–	﹤0.01%	657
2021 Q4	$6K	Sell	187 -3,000	-94%	-$94.4K	﹤0.01%	685
2021 Q3	$107K	Hold	3,187	–	–	0.02%	235
2021 Q2	$127K	Sell	3,187 -5,000	-61%	-$196K	0.03%	230
2021 Q1	$368K	Sell	8,187 -115	-1%	-$6.41K	0.09%	108
2020 Q4	$469K	Buy	8,302 +5,187	+167%	+$258K	0.13%	88
2020 Q3	$148K	Buy	3,115 +115	+4%	+$6.39K	0.05%	155
2020 Q2	$177K	Buy	+3,000	New	+$167K	0.07%	111

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Carolinas Wealth Consulting's IONS Position: Q4 2023 in Review

Carolinas Wealth Consulting sold out of Ionis Pharmaceuticals (IONS) in Q4 2023, closing a stake of 161 shares — an estimated $7.13K sold.

Carolinas Wealth Consulting first reported a position in IONS in Q2 2020 and held it in 14 quarters. The position peaked at $469K in Q4 2020. 363 funds tracked by Wall St. Rank hold IONS as of Q4 2023.

Carolinas Wealth Consulting reported no remaining Ionis Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Carolinas Wealth Consulting sold 161 Ionis Pharmaceuticals shares in Q4 2023, an estimated $7.13K.
Carolinas Wealth Consulting first reported a position in Ionis Pharmaceuticals in Q2 2020 and held it in 14 quarters.
Carolinas Wealth Consulting's Ionis Pharmaceuticals position peaked at $469K in Q4 2020.
363 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2023.

Based on Carolinas Wealth Consulting's 13F filing for Q4 2023, filed 13 Feb 2024.